Diagnostic accuracies of screening for atrial fibrillation by cardiac nurses versus radiographers.
atrial fibrillation
diagnostic accuracy
electrocardiography
screening
Journal
Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219
Informations de publication
Date de publication:
Historique:
received:
01
10
2018
revised:
11
12
2018
accepted:
03
02
2019
entrez:
19
4
2019
pubmed:
19
4
2019
medline:
19
4
2019
Statut:
epublish
Résumé
We examined the diagnostic accuracy of single-lead ECG as assessed by radiographers and 12-lead ECG as assessed by cardiac nurses for the diagnosis of atrial fibrillation (AF). Based on the Danish Cardiovascular Screening Trial, we conducted a population-based, cross-sectional study of 1338 randomly selected Danish men aged 65-74 years with no exclusion criteria. The participants were screened with single-lead ECG during a CT scan assessed by radiographers and 12-lead ECG assessed by cardiac nurses. The diagnostic accuracy was evaluated compared with that produced by a 12-lead ECG assessed by two consenting cardiologists. The study identified 68 participants with ongoing AF, of whom 60 had self-reported AF and 8 had AF detected in the screening. Single-lead ECG assessed for AF by radiographers had a sensitivity of 60.3% (95% CI 47.7 to 72.0), specificity of 97.2% (95% CI 96.2 to 98.1), positive predictive value (PPV) of 53.9% (95% CI 42.1 to 65.5) and negative predictive value (NPV) of 97.9% (95% CI 96.9 to 98.6). 12-lead ECG assessed by cardiac nurses had a sensitivity of 97.1% (95% CI 89.8 to 99.6), specificity of 100% (95% CI 99.7 to 100), PPV of 100% (95% CI 94.6 to 100) and NPV of 99.8% (95% CI 99.4 to 100). Single-lead ECG assessed by radiographers had a moderate sensitivity and PPV but a very high specificity and NPV. Using radiographers may be acceptable for opportunistic screening, in particular if radiographers are thoroughly trained. Thus, 12-lead ECG assessed by cardiac nurses is a potential diagnostic method for the detection of AF.
Identifiants
pubmed: 30997131
doi: 10.1136/openhrt-2018-000942
pii: openhrt-2018-000942
pmc: PMC6443120
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e000942Déclaration de conflit d'intérêts
Competing interests: LF has been a member of the advisory boards for BMS and Pfizer, and has received speaker fees from Bayer, BMS, Boehringer Ingelheim, MSD and Pfizer.
Références
Health Technol Assess. 2005 Oct;9(40):iii-iv, ix-x, 1-74
pubmed: 16202350
Circulation. 2007 Jun 19;115(24):3050-6
pubmed: 17548732
Stroke. 2009 Jan;40(1):235-40
pubmed: 18757287
Eur Heart J. 2013 Sep;34(35):2746-51
pubmed: 23900699
Circulation. 2014 Feb 25;129(8):837-47
pubmed: 24345399
Thromb Haemost. 2014 Jun;111(6):1167-76
pubmed: 24687081
BMC Fam Pract. 2014 Jun 09;15:113
pubmed: 24913608
Am J Cardiol. 2014 Oct 1;114(7):1046-8
pubmed: 25212546
Circulation. 2015 Jun 23;131(25):2176-84
pubmed: 25910800
Eur J Prev Cardiol. 2016 Aug;23(12):1330-8
pubmed: 26464292
Trials. 2015 Dec 05;16:554
pubmed: 26637993
Heart Rhythm. 2016 Jul;13(7):1418-24
pubmed: 26961300
J Am Heart Assoc. 2016 Jul 21;5(7):
pubmed: 27444506
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Europace. 2017 Feb 1;19(2):169-179
pubmed: 28172715
Europace. 2017 Sep 1;19(9):1449-1453
pubmed: 28339578
Circulation. 2017 May 9;135(19):1851-1867
pubmed: 28483832
Lancet. 2017 Nov 18;390(10109):2256-2265
pubmed: 28859943
Europace. 2017 Oct 1;19(10):1589-1623
pubmed: 29048522
PLoS One. 2017 Nov 13;12(11):e0188086
pubmed: 29131836
Europace. 2018 Mar 1;20(3):395-407
pubmed: 29300976
Eur Heart J. 2018 Apr 21;39(16):1407-1415
pubmed: 29340587
JAMA. 2018 Aug 7;320(5):478-484
pubmed: 30088016